Finoriq research workspace
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) SEC Filings & Filing Highlights
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development. Review CRL SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization. Additionally, it has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
- Company
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)
- Ticker
- CRL
- Market Cap
- $10.7B
- Latest Price
- $221.11
- Industry
- Biotech & Pharma
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL).
| Event | Form | Date |
|---|---|---|
| On May 7, 2026, Charles River Laboratories International, Inc. issued a press release providing...The following information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "E... | 8-K2.02 | 2026-05-07 |
| The following twelve directors were elected to serve until our 2027 Annual Meeting of Sharehold...At the Company’s Annual Meeting, the following proposals were adopted by the votes specified below. For more information on the following p... | 8-K5.07 | 2026-05-11 |
| On May 5, 2026, Charles River Laboratories International, Inc. (the “Company”) held its 2026 an...On May 5, 2026, Charles River Laboratories International, Inc. (the “Company”) held its 2026 annual meeting of shareholders (the “Annual Me... | 8-K5.02 | 2026-05-11 |
| Planned Divestiture of CDMO and Cell Solutions BusinessesThe following information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "E... | 8-K7.01 | 2026-02-25 |
| On February 18, 2026, the Company announced the appointment of Glenn Coleman as its Corporate E...On February 18, 2026, the Company announced the appointment of Glenn Coleman as its Corporate Executive Vice President and Chief Financial... | 8-K5.02 | 2026-02-18 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.